Frontlight ResearchEarly access
Taking people in NetherlandsPhase 2
Nivolumab and dendritic cell therapy with surgery for peritoneal mesothelioma
Tests nivolumab and dendritic cell therapy alongside surgery in adults with peritoneal mesothelioma.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Rotterdam, NetherlandsSee the site
- Trial code
- Registry title
- IMMUNOPEC: Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with Peritoneal Mesothelioma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 18 people, planned
- Started
- 1 May 2026
- Expected to end
- 1 Aug 2030
- Type of study
- Interventional
- Record updated
- 16 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with epithelioid peritoneal mesothelioma who are fit for cytoreductive surgery with heated chemotherapy inside the abdomen (CRS-HIPEC). It tests nivolumab and a dendritic cell vaccine (MesoPher) around this surgery.
- Age
- 18 years or older.
- Sex
- Men and women can join.
- Disease stage
- Epithelioid peritoneal mesothelioma confirmed under the microscope. No disease outside the abdomen.
- Earlier treatment
- No more than 10 mg of prednisolone or equivalent per day, and no other immunosuppressive drugs, in the 6 weeks before the first study drug.
Main reasons for not taking part
- Cancer spread outside the abdomen
- Known active serious infection, including HIV, hepatitis B or C, or syphilis
- Pregnant or breastfeeding women
- Known allergy to shellfish
- Serious illness that makes the study treatment too risky
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Histologically confirmed diagnosis of epithelioid peritoneal mesothelioma
- Patients must be at least 18 years old and must be able to give written informed consent
- Fit to undergo CRS-HIPEC (as per standard of care of the treating physician/Institution)
- Ability to return to the study centre for adequate follow-up and vaccinations
- Written informed consent according to the ICH-GCP
- Men must be willing to use an effective contraceptive method during the study and for at least 12 months after the last study drug administration
- Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test just prior to the first study drug administration on day 1, and must be willing to use an effective contraceptive method and for at least 12 months after the last study drug administration
Who cannot take part
- Use of >10 mg of prednisolone or equivalent/day (or other immunosuppressive agents) during the past 6 weeks before the first study drug administration and throughout the study. Prophylactic usage of dexamethasone (steroids) during chemotherapy is excluded from this 6-week interval. Inhaled or topical steroids, and adrenal replacement steroid ≤10 mg daily prednisone equivalent, are permit-ted in the absence of active autoimmune disease
- Extra-abdominal metastatic disease
- Subject with any known active serious infection, including human immunodeficiency virus (HIV), hepatitis B or C virus, or syphilis infection
- Serious chronic or acute illness with an unwarranted high risk for the study treatment
- An organic brain syndrome or other significant psychiatric abnormality which would comprise the study
- Patients with a known allergy to shellfish (may contain KLH)
- Medical or psychological impediment to probable compliance with the protocol
- Pregnant or lactating women
Where in Netherlands
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
About the trial
What the trial wants to find out
To assess the efficacy of (neo-)adjuvant CPI (nivolumab) and DCT (MesoPher) around CRS-HIPEC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- IMMUNOPEC: Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with Peritoneal Mesothelioma
- Plain-language title
- Nivolumab and dendritic cell therapy with surgery for peritoneal mesotheliomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 16 April 2026